155 related articles for article (PubMed ID: 19237713)
1. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Chamberlain MC
Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
[No Abstract] [Full Text] [Related]
2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
3. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
Chamberlain MC
Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
[No Abstract] [Full Text] [Related]
4. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
5. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Chamberlain MC
Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
7. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
10. New agents and new end points for recurrent gliomas.
Brandes AA; Franceschi E
J Clin Oncol; 2011 Mar; 29(9):e245-6; author reply e247. PubMed ID: 21282544
[No Abstract] [Full Text] [Related]
11. Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.
Leal T; Robins HI
Cancer Chemother Pharmacol; 2010 Jan; 65(2):399-401. PubMed ID: 19756604
[TBL] [Abstract][Full Text] [Related]
12. [Angiogenesis suppressing therapy applied to malignant glioma].
Takano S
Gan To Kagaku Ryoho; 2009 Jun; 36(6):941-7. PubMed ID: 19579331
[No Abstract] [Full Text] [Related]
13. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
[TBL] [Abstract][Full Text] [Related]
14. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
Takano S; Mashiko R; Osuka S; Ishikawa E; Ohneda O; Matsumura A
Brain Tumor Pathol; 2010 Oct; 27(2):89-94. PubMed ID: 21046310
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab does not increase the risk of remote relapse in malignant glioma.
Wick A; Dörner N; Schäfer N; Hofer S; Heiland S; Schemmer D; Platten M; Weller M; Bendszus M; Wick W
Ann Neurol; 2011 Mar; 69(3):586-92. PubMed ID: 21446027
[TBL] [Abstract][Full Text] [Related]
16. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.
Misch M; Czabanka M; Dengler J; Stoffels M; Auf G; Vajkoczy P; Stockhammer F
Anticancer Res; 2013 May; 33(5):2093-8. PubMed ID: 23645760
[TBL] [Abstract][Full Text] [Related]
17. Therapy for recurrent malignant glioma in adults.
Mrugala MM; Kesari S; Ramakrishna N; Wen PY
Expert Rev Anticancer Ther; 2004 Oct; 4(5):759-82. PubMed ID: 15485312
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Chamberlain MC
Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
[No Abstract] [Full Text] [Related]
19. Avastin: more questions than answers. .
Desjardins A; Sampson JH
J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
[No Abstract] [Full Text] [Related]
20. Bevacizumab for recurrent hemangioendothelioma.
Trautmann K; Bethke A; Ehninger G; Folprecht G
Acta Oncol; 2011 Jan; 50(1):153-4. PubMed ID: 20950228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
